Skip to main content
    A

    Ascendis Pharma AS (ASND)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $271.73
    -3.66 (-1.33%)

    Market Cap: $18.06B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Ascendis Pharma AS (ASND) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Ascendis Pharma AS (ASND) trades at 13.5x sales and 10.8x book value. Its P/S of 13.5x is below its 5-year median of 23.9x.

    Current Multiples

    ASND reports in EUR, so earnings multiples appear here only when its per-share earnings can be confirmed. Its free cash flow yield is 3.2%.

    MultipleValue
    P/E (trailing)N/A
    Forward P/EN/A
    Price to sales13.5x
    Price to book10.8x
    EV/EBITDA60.8x
    Price to FCF31.6x
    EV/FCF30.6x
    PEGN/A
    FCF yield3.2%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 90.5% below 141.6x.

    MultipleCurrent5-year median10-year median
    P/S13.5x23.9x141.6x
    Medians of month-end values through Oct 2026: 59 months (5-year) and 100 months (10-year).

    Valuation History

    Over the 9 of the 10 year ends shown that have a P/S, its P/S ranged from 15.8x in 2025 to 811.8x in 2021. 2025 was the lowest of those years.

    Year endPriceP/SP/B
    2025$213.2415.8xN/A
    2024$137.6720.9xN/A
    2023$125.9524.4xN/A
    2022$122.13127.9x24.3x
    2021$134.53811.8x7.2x
    2020$166.78N/A8.8x
    2019$139.12425.0x10.0x
    2018$62.65223.8x8.5x
    2017$40.06766.8x6.9x
    2016$20.24104.9x3.5x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    P/E history is shown only for companies that report in US dollars.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About ASND

    Is ASND stock overvalued?

    GNG's valuation label for ASND is Undervalued.

    What is ASND's price to sales ratio?

    Ascendis Pharma AS has a price to sales ratio of 13.5x.